Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Next Previous
Trial Profile

Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Eltrombopag (Primary)
  • Indications Anaemia; Aplastic anaemia; Neutropenia; Pancytopenia; Thrombocytopenia
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 22 Mar 2023 Planned End Date changed from 30 Jan 2024 to 30 Jan 2029.
    • 15 Sep 2021 Results (n=178) of update on long-term outcomes in patients treated with IST and EPAG on a prospective phase 2 trial, with largest cohort and longest follow-up to date published in the Blood.
    • 29 Jun 2020 Status changed from active, no longer recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top